Literature DB >> 27908593

Progress in PARP inhibitors beyond BRCA mutant recurrent ovarian cancer?

Antonio González Martín1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27908593     DOI： 10.1016/S1470-2045(16)30621-0

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  7 in total

Review 1.  PARP inhibitors: Synthetic lethality in the clinic.

Authors:  Christopher J Lord; Alan Ashworth
Journal:  Science       Date:  2017-03-16       Impact factor: 47.728

Review 2.  PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.

Authors:  Geraldine O'Sullivan Coyne; Alice P Chen; Robert Meehan; James H Doroshow
Journal:  Drugs       Date:  2017-02       Impact factor: 9.546

3.  The effects of genomic germline variant reclassification on clinical cancer care.

Authors:  Thomas P Slavin; Sophia Manjarrez; Colin C Pritchard; Stacy Gray; Jeffrey N Weitzel
Journal:  Oncotarget       Date:  2019-01-11

Review 4.  Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation.

Authors:  Win Topatana; Sarun Juengpanich; Shijie Li; Jiasheng Cao; Jiahao Hu; Jiyoung Lee; Kenneth Suliyanto; Diana Ma; Bin Zhang; Mingyu Chen; Xiujun Cai
Journal:  J Hematol Oncol       Date:  2020-09-03       Impact factor: 17.388

5.  RNA-Binding Motif Protein 11 (RBM11) Serves as a Prognostic Biomarker and Promotes Ovarian Cancer Progression.

Authors:  Chunhong Fu; Ming Yuan; Jie Sun; Gang Liu; Xiaojuan Zhao; Wei Chang; Zhongling Ma
Journal:  Dis Markers       Date:  2021-08-14       Impact factor: 3.434

Review 6.  Targeting DNA repair pathway in cancer: Mechanisms and clinical application.

Authors:  Manni Wang; Siyuan Chen; Danyi Ao
Journal:  MedComm (2020)       Date:  2021-12-07

Review 7.  Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer.

Authors:  Margarita Romeo; Juan Carlos Pardo; Anna Martínez-Cardús; Eva Martínez-Balibrea; Vanesa Quiroga; Sergio Martínez-Román; Francesc Solé; Mireia Margelí; Ricard Mesía
Journal:  Int J Mol Sci       Date:  2018-10-19       Impact factor: 5.923
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.